Minneapolis Clinical Trials
2300 LDL Protein Study
Purpose: to evaluate the safety and tolerability of a potential new drug for atherosclerotic cardiovascular disease (ASCVD) in patients with kidney impairment compared to those with normal kidney function.
4 nights
7 visits
Participate in a clinical study for an investigational medication for the treatment of cardiovascular disease.
This study has 1 screening appointment, 1 inpatient stay of 4 nights/ 5 days and 6 outpatient visits.
Reimbursement for study participation will be provided for time and travel of up to $4,730.
Transportation may be arranged to and from the Nucleus clinic for appointments.
This study has been reviewed by an independent ethics committee.
Call 612-315-6490 to discuss your eligibility today!
Eligibility
Age: 18-85
BMI: 19-42 kg/m2
Medication: Approved on case-by-case basis with our medical team
Smoking Status Non-smokers and smokers. No smoking allowed inside research unit; participants may use nicotine replacement therapy while inpatient.
Compensation: Up to $4,730